Embed Size (px)
Citation preview
1
Lair Ribeiro,MD,FACC - author of 38 books (15 best sellers), 26 of which are
translated into other languages and available in more than 40 countries in the area
of self-knowledge and medical Science. Also author of more than 100 scientific
papers published in American medical journals.
Dr. Ribeiro has had the opportunity to live 17 years in the USA and work in three
American universities - Harvard Medical School, Baylor College of Medicine and
Thomas Jefferson University. In addition, he has been the medical director of
Merck Sharp & Dohme and the,executive diretor, becoming vice president of Ciba
Corporation (now Novartis).
He currently works in several countries in South America, Central America, North
America and Europe, giving lectures and Workshops on Personal / Professional
Development and Courses for Health Professionals in Bioidentical hormones.
In addition, Dr. Lair Ribeiro is Professor and coordinator of the Post-Graduation
Course lato sensu of Uningá- University Center Ingá named - NUTRITIONAL
ADEQUACY AND MAINTENANCE OF ENDOCRINE HOMEOSTERASE - PREVENTION AND TREATMENT OF DISEASES RELATED TO AGING.
CURRICULO VITAE Lair Geraldo Theodoro Ribeiro, M. D., F.A.C.C.
EDUCATION
Educational Foundation Machado Sobrinho, Degree Year Juiz de Fora (MG), Brazil B.S. 1967
Medical School of the Federal University M.D. 1972 Juiz de Fora (MG), Brazil
INTERNSHIP AND POSTGRADUATE TRAINING
Residency in Cardiology, Pontificia Universidade Catolica of Rio de Janeiro (RJ), Brazil 1973
Research Fellow in Medicine, Peter Bent Brigham Hospital and Harvard Medical School, Boston (MA), USA 1976-1978
Fellow in Cardiology, The Methodist Hospital Baylor College of Medicine, Houston (TX), USA 1978-1980
2
TEACHING/RESEARCH/MANAGERIAL EXPERIENCE
Teaching Assistant in Anatomy, Medical School of the Federal University of Juiz de Fora (MG), Brazil 1969-1971
Teaching Assistant in Cardiology, Medical School of the Federal University of Juiz de Fora (MG), Brazil 1971-1972
Instructor in Cardiology, Post-Graduate Course, Pontificia Universidade Catolica of Rio de Janeiro (RJ), Brazil 1974
Assistant of Professor in Cardiology, Medical School of Barbacena (MG), Brazil 1975-1976
Assistant Director of Deborah Cardiovascular Research Institute, Browns Mills (NJ), USA 1980-1982
Lair G.T.Ribeiro,M.D. Page 2 Curriculum Vitae TEACHING /RESEARCH/MANAGERIAL EXPERIENCE (Cont.)
Adjunct Assistant Professor Thomas Jefferson College Of Medicine 1981-1984 Philadelphia (PA), USA.
Director, Clinical Research Merck Sharp & Dohme Research 1982-1985 Laboratories, West Point (PA), USA.
Adjunct Associate Professor Thomas Jefferson College of Medicine Since 1984 Philadelphia (PA), USA.
Executive Director, Cardiovascular Clinical Research, CIBA-GEIGY Corporation 1985-1988 Pharmaceutical Division, Summit (NJ), USA.
3
Acting Vice President, Cardiovascular Drug Sept. 1988- Development, CIBA-GEIGY Corporation Jan. 1989 Pharrnaceutical Division, Summit (NJ), USA.
Chairman of Transderm-Nitro Defense Sept. 1988- CIBA-GEIGY Corporation Jan. 1989 Pharmaceutical Division, Summit (NJ), USA.
EXTRACURRICULUM EDUCATION
NLP Practioner Certification, New York NLP 1985-1986 Institute, New York (NY), USA.
Management Development Program, Northeastern 1987 University, Boston (MA), USA.
NLP MasterCertification, NLP Comprehensive, 1990 Boulder, (CO), USA.
Lair G.T.Ribeiro,M.D. Page 3 Curriculum Vitae MEDICAL PUBLICATIONS
(See attached list) OTHER AFFILIATIONS
1974 Brazilian Cardiology Society 1980 American Federation of Clinical Research 1981 New York Academy of Science 1983 American College of Cardiology 1983 Who's Who in Frontier Science Technology 1985 American Hear Association's Councils of Circulation and Basic Science 1986 National Association of Neuro-Linguistic Programming
SERVICE EXPERIENCE - Brazil
4
Banco do Brasil Employee - Teófilo Ottoni (MG) 1964-1966 Cardiologist, Pro-Cardiaco Hospital 1972-1974
Cardiologist, Saint Luke Hospital - Teófilo Ottoni (MG) 1974-1976 PRESENT POSITION
President, International Support, Inc. Since Feb. Scientific and Management Consultants 1989 Watchung (NJ)
PUBLICATIONS MANUSCRIPTS PUBLISHED 1. Chiariello M. Ribeiro LGT, Davis MA and Maroko PR. "Reverse Coronary Steal"
Induced by methoxamine followlng coronary artery occlusion in dogs. Circulation 56.809-815, 1977.
2. Ribeiro LGT, Hillis LD, Louie Eric K, Davis MA. Maroko PR and Braunwald E.
A method for demonstrating the efficacy of intervention designed to limit infarct size followlng coronary occlusion Cardiovasc Res 12.334-340, 1978.
3. Maroko PR, Kloner RA, Yasuda T, Ribeiro LGT, Maclean D and Braunwaid E. Recent
lnvestigations on attempts to limit infarct size. Chapter in acute and long term medical rnanagement of myocardial ischemia. L. Wilheimsen and S. Hjalmarson, editors, Lindgren and Soner, Molndal. 373-387, 1978.
4. Braunwald E, Kloner RA, Hillis LD, Maclean D, Ribeiro LGT and Maroko PR: The use of
hyaluronidase in the limitation of infarct size following acute coronary occlusion. Chapter in acute and long term medical management of myocardial ischemia. L Wilhelmsen and A Hjalmarson, Editors, Lingren and Soner, Molndal 358-372, 1978.
5. Ribeiro LGT, Louie EK, Hillis LD, Davis MA and Maroko PR. Early augmentation of R
wave voltage after coronary artery occlusion. A useful index of myocardial injury. J Electrocardiol 12:89-95, 1979.
6. Ribeiro LGT, Louie EK, Davis MA and Maroko PR: Augmentation of collateral blood
flow to the ischemic myocardium by oxygen inhalation following experimental coronarv artery occlusion Cardiovasc Res 13.160-166, 1979
7. Maroko PR, Maclean D, Ribeiro LGT and Braunwald E. Pharmacological limitation of
infarct size. Enzymatic elecrocardiographic and rnorphological studies in the experimental animal and man. Enzymes in Cardiology. Diagnosis & Research Editor, DJ Hearse, The John Wiley Publishing Co, 1979.
8. Ribeiro LGT, Hooking G, Brandon TA, Reduto LA and Miller RR: Hyperemia bordering
5
ischemic myocardium in experimental myocardial infarction. Cardiovasc Res 14.345-351, 1980.
9. Quinones MA, Young JB, Waggoner AD, Ostojic MC, Ribeiro LGT and Miller RR: Pulsed
doppler echocardiography: An accurate noninvasive detector of left-sided valvular insufficiency. Br Heart J 44:612-620, 1980.
10. Ribeiro LGT, DeBauche TL, Brandon TA, Reduto LA, Maroko PR and Miller RR
Comparative efects of verabamil and nifedipine on reactive hypermia, and ventricular arrhythmias during coronary artery reperfusion. Eur Heart J (Suppl B): 31-35, 1980.
11. Ribeiro LGT and Yasuda T. Coronary reperfusion in rats - Beneficial effects of
verapamil. Arq Bras Cardiol 35.135-138, 1980. 12 Ribeiro LGT, Brandon TA, Hopkins G, Reduto L.A, Taylor A and Miller RR. Protacyclin
in experimental myocardial ischemia. Effects on hemodynamic regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47.835-840, 1981.
13. Young JB, Quinones MD, Waggoner AD, Ostojic MC, Ribeiro LGT and Miller RR: Pulsed
doppler echocardiographic assessment of left-sided valvular insufficiency Noninvasive cardiovascular diagnosis Editor, EB Diethrich, The PSG Publishing Company, Inc. 575-584, 1981.
14. Ribeiro LGT, Brandon TA, DeBauche TL, Maroko PR and Miller RR: Antiarrhythmic and
hemodynamic effects of calcium channel blocking agents during coronary arterial reperfusion. Am J Cardiol 48:69-74, 1981.
15. Ribeiro LGT and Maroko PR. Reduction in infarct size by verapamil administration
Arq Bras Cardiol 36:1-4, 1981. 16. Maroko PR, Chiariello M and Ribeiro LGT. The influence of vasodilators and
vasoconstrictors on coronary collateral flow after experimental coronary artery occlusion. Les Alpha-Bloquants. Pharmacologie Experlmentale Et Clinique, Baumann, D, et al, Editors. Paris Symposium International, Masson PubIishing Company, 193-202, 1981.
17. Iwasaki T, Ribeiro LGT, Faria DB Cheung W-m and Maroko PR: The importance of the
source of hyaluronidase in determining its effectiveness in reducing infarct size Am Heart J 102 324-329, 1981.
18. Yasuda T, Holmarl BL, Ribeiro LGT, Alpert JS and Maroko PR. Accuracy of serial 12
lead electrocardiograms in localizing myocardial infarctions. J Electrocardiol 15(2):181-188, 1982.
19. Miller RR, Ribeiro LGT, DeBauche TL and Brandon TA: Effects of prostacyclin and
nitroprusside on mortality following experimental coronary artery occlusion, Chapter 13, Platelets and Prostaglandins in Cardiovascular
6
Disease, Metha, J an Metha, P, Editors Mount Kisco, NY, Futura Publishing Company, 251-264. 1981.
20. Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL, Jr, Ribeiro
LGT and Miller RR. A new simplified and accurate; method for determining ejection fraction with two-dimensional echocarography Circulation 64.744-753, 1981.
21. Ribeiro LGT, Hillis LD and Maroko PR. Evolution of epicardial R wave voltage
following experimental coronary artery occlusion Cardiovasc Res 15.425-429, 1981.
22. Ribeiro LGT, Spadaro J, Brandon TA, Kim H-S, Titus JL, Maroko PR and Miller RR.
Effects of methoxy-verapamil (D600) on mortality and infarct size after coronary artery occlusion in rats. Arq Bras Cardiol 37;85-88, 1981.
23. Ribeiro LGT and Lefer AM. Etiology an pathophysiology of coronary artery spasm
chapter 2, Coronary Artery Spasm Robert A Char!ne. Editor, rlount Kisco, NY, Futura Puhlishing Company, 39-64, 1983.
24. Ribeiro LGT, Brandon TA, Horak JK, Ware JA, Miller RR and Solis RT: Inhibition of
platelet aggregation by verapamil: Quantification by in vivo and in vitro techniques. Cardiovasc Pharm 4 170-173, 1982.
25. Ribeiro LGT, Cheung W-m and Maroko PR. Influence of the extentof the zone at risk
on the effectiveness of drugs in reducing infarct size Circulation 66: 181-186, 1982.
26. Yasuda T, Ribeiro LGT and Maroko PR. Effect of hyaluronidase on experimental
cerebral infarct size an mortality. Laboratory Investigation 46:400-404, 1982.
27. Maroko PR, Ribeiro LGT and Golderg S: Acute myocardial infarction - Coronary
thrombosis and salvage of the ischemic myocardium, coronary artery spasm and thrombosis, and clinical aspects. Goldberg, S (ed) FA Davis, CO., Phila., PA, Cardiovascular Clinic Series, 14:(1 ) 191 -202, 1983.
28. Ribeiro LGT, Zalewski A and Maroko PR: Limitation of infarct size: Mechanisms o
interventions, methods of evaluation and clinical applications. In Treatment of Myocardial Ischemia, Ed Pedro Zarco, Editorial Alhampra S A, Madrid Spain, 1982.
29. Hortak JK, Brandon TA, Ribeiro LGT, Ware JA Miller RR and Solis RT: Effects of
Ethanol and Hemolysis on In Vivo and In Vitro Platelet Aggregation J Cardiovasc Pharm 4 (6). 1037-1041, 1982.
30. Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR: The effects of lidocaine and
droxicainide on myocarial necrosis. J Am Coll Cardiol 1(6).1447-1452, 1983.
7
31. Endo T, Ribeiro LGT, Cheung W-m, Faria DB, Petranto MS and Maroko PR
Relationship between the extent of the hypoperfused zone of the myocardium and the occurrence of ventricular fibrillation. Am Heart J 105(6): June, 1983.
32. Ribeiro LGT and Davies RO: Reduction in Cardiac Death and Reinfarction Rates
Caused by Beta-Blockers After Acute Myocardial Infarction. Rev Port Cardiol 2(5):389-392, 1983.
33. Ribeiro LGT: Beneficial effects of beta-blockade on secondary prevention. Arq
Bras Cardiol 40(2): 73-76, 1983. 34. Sweet CS, Gaul SL, Reitz PM, Blaine EH and Ribeiro LGT: Mechanism of action of
enalapril in experimental hypertension and acute left ventricular failure. J Hypertension 1 (Suppl 1):53-63, 1983.
35. Vik-Mo H, Maroko PR and Ribeiro LGT: Comparative effects of proranolol, timolol and metoprol on myocardial infarct after experimental coronary artery occlusion. J Am Coll Cardiol 4(4): 735-741, 1984. 36. Sweet CS, Ludden CT, Frederick CM and Ribeiro LGT: Hemodynamic effects of
antiotensin and renin inhibition in dogs with acute left ventricular failure. Am J Med 77:7-12, 1984.
37. Sweet CS, Ludden CT, Frederick CMK, Bush LR and Ribeiro LGT: Comparative
hemodynamic effects of enalaprilat (MK-422), a converting enzyme inhibitor and a renin inhibitor in dogs with left ventricular failure. J C Pharmacol 6:1067-1075, 1984.
38. Hock CE, Ribeiro LGT and Lefer AM: Preservation of ischemic myocardium
by a new converting enzyme inhibitor, enalprilic acid, in acute rnyocardial infarction Am Heart J 109 222-228, 1985.
39. Vlasses PH, Ribeiro LGT, Rotmensch HH, Bondi JV, Loper AE, Hichens M,
Duniay MC and Ferguson RK: Initial evaluation of transdermal Timolol, serum concentrations and beta-blockade. J Cardiovasc Pharmacol 7.245-250, 1985.
40. Ribeiro LGT and Kasdin SL: Prognosis after an acute myocardial infarction
secondary prevention. Rev Lat Car 5(6).561-569,1984. 41. Ribeiro LGT and Walker J F: Therapeutic applications of angiotensin
converting enzyme inhibitors. Rev Braz Med 42(7).242-246, 1985. 42. Vik-Mo H, Yasay G, Ribeiro LGT and Maroko PR: Comparatlve effects of
dobutamine and corwin, a beta-adrenergic partial agonist, in experimental left ventricular failure. J Cardiovasc Pharmacol 7 784-790, 1985.
8
43. Sweet CS, Ludden CT, Freerick CM, Ribeiro LGT, Nussberger J. Slater EE and Blaine EH: Hemodynamic effects of synthetic atrial natri uretic factor (ANF) in dogs with acute ventricular failure. EurJ Pharmacol 115:267-276, 1985.
44. Davis RF, DeBoar LW, Yasuda T, Rude RE, Ribeiro LGT and Maroko PR.
Reglonal myocardial lidocaine concentration determines the antlysrythmic effect in dogs after coronarv artery occlusion. Anesthesiology 62(2):155-60, 1985.
45. Ribeiro LGT and Kasdin SL: Identiflcation of hign risk patients after an
acute myocardial infarction Therapeutlc approach for secondary prevention Arq Bras Cardiol 44(3) 207-212, 1985.
46. Sweet CS, Ludden CT, Adkins E, Seymour AA, Emmert S and Ribeiro LGT:
Enalapril in exerimental hypertension and acute heart failure: comparison with calcium channel blocker. J Cardiovasc Pharmacol 8(Suppl. 1):S 15 - S 19, 1986.
47. Vik-Mo, Hjos OD, Neelv JR, Maroko PR and Ribeiro LGT: Limitation of
myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium. Am Heart J 111(6): 1048 - 1054. 1986.
48. Lefer DJ, Hock CE, Ribeiro LGT and Lefer AM: Effects of lisinopril, a new
angiotensin converting enzyme inhibitor in a cyro-injury model of chronic left ventricular failure. Meth and Find Exptl Clin Pharmacol 8(6) 357-362, 1986.
49. Ribeiro LGT, Kasdin SL, Snyder DL, Fisher MB and Irvin JD. Beneficial
effects of timolol in digitalized patients with atrial fibrillation and a rapid ventricular response Arq Bras Cardiol 46(3): 211-215,1986.
50. Vik-Mo H, Hastie R. Chir B and Ribeiro LGT : Hemodynamic and metalic
evaluatlon of an acute left ventricular failure modelael induced y coronary artery embolization. Arq ras Carcdiol 48(3).13 g-145, 1987,
51. Ribeiro LGT Hypertension. A paramount cardiovascular risk-factor in
the western world. Arq Bras Cardiol 49(4):245-248, 1987. 52. Sweet CS, Emmert SE, Stabilito ll and Ribeiro LGT: Increased survival in
rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 1 10(6).639-642, 1987.
9
53. Lin SK and Ribeiro LGT: Kinetics of transdermal clonidine Arch Intern Med 147:1681, 1987.
54. Brow L, Nusbaum IM and Ribeiro LGT: Quality of life - now asess it in clinical trials. Arq Bras Cardiol 50(6): 365-368, 1988. 55. Islami Y, Ribeiro LGT: Lipid lowering effects on cardiovascular morbility
and mortality. Clinical evidence and therapeutic guidelines. Arq Bras Cardiol 51 ( 1 ) 43-48,1988.
56. Smith EF, Egan JW, Goodman FR, Zimmerman MB, Webb RL and Ribeiro LGT.
Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat. Pharmacology 37:254-263, 1988.
57. Ribeiro LGT, Price BA and Irvin JD: Antiarrhythmic effects of timolol in
patients with ventricular arrhythmias Arq Bras Cardiol 51(4) 359-364, 1988.
58.Ribeiro LGT, Hopkins DG, Brandon TA, Reduto LA and Miller RR. Quantification of hyperemia bordering ischemic myocardium in experimental myocardium infarction. Cardiovascular Research, 1980, 14, 345-351. 59.Ribeiro LGT, Hillis LD, Louie ED, Davis MA, Maroko PR and Braunwald, E. A method for demonstrating the efficacy of interventions designed to limit infarct size following coronary occlusion: beneficial effects of hyaluronidase. Cardiovascular Research, 1978, 12, 334-340. 60.Ribeiro, LGT. Sal: Ingerir ou não ingerir? Vilão ou Herói? Brazilian Journal of Surgery and Clinical Research-BTSCR. Vol 13.n.1, pp. 06-11 (Dez 2015-Fev2016) 61.Ribeiro, LGT. Sal: Deficiência de vitamina B12 – uma epidemia invisível ao serviço de saúde. Brazilian Journal of Surgery and Clinical Research-BTSCR. Vol 13.n.1, pp. C10-C13 (Dez 2015-Fev2016) PUBLICATIONS ABSTRACTS 1. Duarte GM, Ribeiro LGT and Carneiro RD. Acao ao verapamil na insuficiencia
coronariana--avaliacao pelo teste ergometrico(in Portuguese). Arq Bras Cardiol 28 (Suppl 2):288, 1975.
2. Ribeiro LGT, Louis EK, Davis MA and Maroko PR. Beneficial effectof 100%
breathing on redistribution of regional myocardialblood flow. Clin Res 25:248A, 1977.
10
3. Ribeiro LGT, Hillis LD, Fishein MC, Davis MA, Maroko PR and Braunwald E.
A new technique for demonstrating the efficacy of interventions designed to limit infarct size following coronary occlusion: beneficial effect of hyaluronidase. Clin Res 25:248A 1977.
4. Ribeiro LGT, Louie EK and Maroko PR: Influencia da inalacao de oxigenio na
redistribuicao do fluxo coronarano (in Portuguese) Arq Bras Car. 54(Suppl 3): 232, 1977.
5. Ribeiro LGT, Louie EK, Hillis LD, Davis MA and Maroko PR Early increases in
R wave voltage after coronary artery occlusion: A useful index of ischemia. Clin Res 26:264A, 1978.
6. Maroko PT, Ribeiro LGT, Kloner RA, Hillis LD and Braunwald E. Can
myocardial damage following coronary occlusion really be reduced? Proceeding of VllI World Congress of Cardiology, 1978.
7. Maroko PR, Ribeiro LGT, Kloner RA, Ingwall JS and Caride VJ. Transport of
ATP y liposomes into the schemic myocardium Circulation 58 (4) 11 58, 1978.
8. Maroko PR, Yasuda T, Ribeiro LGT, Bingham J, McKusick K, Fishbein MC
and Strauss W: Global and regional left ventricular function by radionuclide ventriculography after coronary occlusion in rats. Its evolution and its correlation to infarct size. Circulation 58(4)11 - 175, 1978.
9. Ribeiro LGT, Yasud T, Lowenstein E, Braunwald E and Maroko PR. Compara
tive effects of anatomic infarct size of verapamil, ibuprofen and morphine-promethazine-chlorpromazine combination. Am J Cardiol 43.396, 1979.
10. Davis RF, Yasuda T, Deboer L, Ribeiro LGT, Rude R, Davis MA, Ronfeld RA
and Maroko PR: Determinants of antiarrhythmic efficacy of lidocaine in acute myocardial infarction Am Cardiol 43:371, 1979.
11. Young JB, Quinones MA, Waggoner AD, Ostojic M, Ribeiro LGT, Attar and
Miller RR. Detection of prosthetic paravalvular leak.superiority of pulsed doppler echocardiography to clinical assessment and M-mode echocardiography. Clin Res 27:218A, 1979.
12. Ostojic MC, Quinones MA, Waggoner AD, Ribeiro LGT, Young JB, O’Donnell MJ
and Miller RR. Pulsea doppler echocardiographic assessment of aortic insufficiency: Diagnostic accuracy and quantification of severity (submitted to publication) Clin Res 27:192A, 1979.
11
13. Young JB, Quinones MA, Ribeiro LGT, Waggoner AD, OstoJic M, Shah A and Miller RR: etection of mitral regurgitation y pulsed dopp!er ecocardiogranY dlagnostic accuracy of the time nterval histogram. C 1 in Res 27 1 96A. 17
14. Ribeiro LGT and Yasuda T: Reperfusao coronariana em ratos - efeitos
beneficos do verapamil. (in Portuguese). Arq Bras Cardiol. Suplemento ao Congresso 25, 1978
15. Maroko P, Ribeiro LGT, Hillis LD and Braunwald E: Sinais electro
cardiograficos de necrose em pacientes com infarto agudo do miocardio -- Efeitos beneficos ao Hialuronidase (in Portuguese). Arq Bras Caraiol. Suplemento do Congresso 414, 1978.
16. Hillis LD, Ribeiro LGT, Maroko PR and Braunwald E: Infarto experimental do
miocardio-nova tecnica para medir alteracoes ao seu tamanho (in Portuguese). Arq Bras Cardiol. Suplemento do Congresso 279, 1978.
17. Miller RR, Ribeiro LGT, Brandon TA, Hopkins DG, Reduto LA and Taylor AA:
Effects of Prostacyclin on regional myocardlal blood flow, hemo Dynamics, infarct size and mortality after experimental coronary occlusion. Clin Res 27.199A, 1979.
18. Ribeiro LGT, Brandon TA, Hopkins DG, Reduto L and Miller RR: Identification
and quantification of a hyperemic zone bordering myocardial ischemic area. Clin Res 27:198A. 1979.
19. Ribeiro LGT, Brandon TA and Miller RR. Mortality after coronary artery
occlusion-beneficial effects of D-600 (Methoxi-Verapamil) Clin Res 27:198A, 1979.
20. Ribeiro LGT, Yasuda T, Lowenstein E, Maroko PR and Braunwald E. Reducao
no tamanho do infarto ao miocardio pelo uso do verapamil (in Portuguese). Arq Bras Cardiol 32:Supl 1-176, 1979.
21. Young JB, Ribeiro LGT, Quinones MA, Waggoner AD, Ostojic M and Miller RR.
Importancia da doppler ecocardiografia no diagnostico e evaliacao da insufficiencia aortica e mitral (in Portuguese). Arq Bra Cardiol 32;Supl 1-51, 1979.
22. Verani MOS, Ribeiro LGT and Miller RR: Cintilografia cardiaca com thallium
durante esforco-correlacoes com electracardiograme de esforco e cinecoronariografia (in Portuguese). Arq Bras Cardiol 2 Suppl 1-159, 1979.
23. Spadaro J, Ribeiro LGT, Brandon TA, Hare C and Miller RR: Oclusao
coronariano -- Reducao na mostalidade pelo methoxiverapamil (D-600) (in Portuguese) Arq Bras Cardiol 32: Suppl 1-186, 1979.
12
24. Ribeiro LGT, Quinones MA, Reduto LA, Winters WL and Miller RR. Assessment of left ventricular regional wall motion with two-dimensional echocardiography and gated cardiac imaging comparison to angiography. Circulation 59:11 - 137, 1979.
25. Miller RR, Ribeiro LGT, Brandon TA, Hopkins and Reduto LA: Reduction in
mortality independent of infarct size by nitro-prusside in experimental coronary artery occlusion. Circulation 59:11-124, 1979.
26. Hopkins D, Pratt CM, Ribeiro LGT and Miller RR: Predictors of cardiac
mortality in patients with severe ST-segment depression on treadmill stress testing. Circulation 59:11-266, 1979.
27. Quinones MA, Reduto LA, Nelson JG, Ribeiro LGT, Young JB, Winters WL and
Miller RR. A new simplified method for determining left ventri cular ejection fraction by two-dimensional echocardiography. Circulation 59:11- 1979.
28. Fuller CM, Pratt CM, Nussey GA, Ribeiro LGT, Taylor AA and Miller RR:
Antiarrhythmic efficacy of propranolol immediately following coronary bypass surgery. Circulation 59:184, 1979.
29. DeBauche TL, Ribeiro LGT, Brandon TA and Miller RR Value of re-coronary
artery occlusion heart rate in predicting post-occlusion and reperfusion ventricular fibrillation in the experimental animal Clin Res 27:226A, 1979.
30. Ribeiro LGT, Quinones MA, Reduto LA, Del Ventura L, Waggoner AD, Nelson
JG, Winters WL and Miller RR. Left ventricular segmental wall motion: gated cardiac blood pool imaging versus two-dimensional echocardiography. Clin Res 27.733A, 1979.
31. Brandon TA, Ribeiro LGT, HopKins DG, Reduto LA and Miller RR. Effects cf
lidocaine on hemodynamics, regional myocardial blood flow, infarct size and mortality Clin Res 27:725A, 1979.
32. Pratt CM, Nussey GN, Hopkins DG, Kanon S, Ribeiro LGT, DeBakey ME and
Miller RR. Follow-ur of a high-ris onset of coronary artery alsease patients wit marke lscnemic resDonse to exercise: comparison of mealcal and surglcai grouc. Clin Res 27:72A, 1979
33. Ribeiro LGT, Brandon TA, Horak SK, Solis RS and Miller RR: Inhibition of
platelet aggregation y verapamil quantification by in vitro and in vivo techniques Clin Res 27.7A, 1979
13
34. Ribeiro LGT, DeBauche TL, Brandon TA, Reduto LA and Maroko PR: Verapamil and hifedipine during coronary artery reperfusion: effects on ventricular arrhythmias and regional myocardial blood flow. Clin Res 27;773, 1979.
35. Ribeiro LGT, Quinones MA, Reduto LA, Del Ventura L, Waggoner AD, Nelson
JG, Winters WL and Miller RR. Left ventricular segmental wall motion: comparison of gated cardiac blood pool imaging with two-dimensonal echocsardiography. Clin Res 28:205A, 1980.
36. Ribeiro LGT, Brandon TA, Horak JK, Solis RT and Miller RR: Documentation of
inhibition of platelet aggregation by verapamil quantification by in vitro and in vivo techniques. Clin Res 2:204A, 1980.
37. Solis RT, Ribeiro LGT, Horak JK, Brandon TA and Miller RR: adrenerglc
inhibition of platelet aggregation in vitro and in vivo. Clin Res 28:244A, 1980.
38. DeBauche TL, Brandon TA, Ribeiro LGT, Sybers HD, Thompson W and Miller
RR: Inhibition of platelet aggregation in ischemic myocardium and antiarrnythmic effects of prostacyclin in experimental artery occlusion. Clin Res 28:165A, 1980.
39. Ribeiro LGT, Hillis LD and Maroko PR: Evolution of epicardial R wave
voltage following experimental coronary artery occlusion. Clin Res 28:205A, 1980.
40. Ribeiro LGT, Cheung W-m, Miller R and Maroko PR. Effects of metnoxy
verapamil, a new calcium blocker, on the extent of myocardial necrosis using artoradiography to assess the myocardium at risk. Clin Res 28.205A, 1980.
41. Pratt CM, Nussey G, Hopkins DG, Kanon D, Ribeiro LGT, DeBakey ME and Miller
RR: Long Term edical surgical follow-up of a high risk subset of coronary artery disease patients with marked ischemic response to exercise. Clin Res 28:203A, 1980.
42. Ribeiro LGT, DeBauche TL, Brandon TA, Reduto LA. Maroko PR and Miller RR:
Comparative effects of verapamil and nifedipine on reactive hypermea and ventricular arrhythmias during coronary artery reperfusion. Am J Cardiol 45:46 1, 1980.
43. Cheung W-m, Ribeiro LGT and Maroko PR: Is the effectiveness of a drug in
reducing myocardial inJjry depenaent on the extent of the zone at risk? Circulation, 62(Suppl 111) 314, 1980.
14
44. Maroko PR, Ribeiro LGT, Yasuda T, Davis RF, DeBoer LWV, Strauss HW,
Leinbach RC and Gold HK: Effect of interventions on the protection of the ischemic myocardium in experimental animals and in patients. Proceedings of VIII European Congress of Cardiology Page 116. June, 1980.
45. Ribeiro LGT, Brandon TA, Horak JK, Solis RT and Miller RR: Inhibition of
platelet aggregation by verapamil: futher rationale for the use of calcium antagonists in coronary artery disease Circulation, 62 (Suppl III): 111-293, 1980.
46. DeBauche TL, Brandon TA, Ribeiro LGT, Sybers HD and Miller RR:
Comparative lnhibitory actions of prostacyclin and nitro-prusside on platelet deposition in ischemic myocardium and ventricular fibrillation following coronary artery occlusion. Circulation 62(Suppl III): III-309, 1980.
47. Endo T, Ribeiro LGT, Faria DB, Cheung W-m, Petranto M and Maroko PR:
Correlation between the extent of the zone of hypoperfusion and the incidence of ventricular fibrillation after experimental coronary artery occlusion. Clin Res 29.188A, 1981.
48. Maroko PR, Cheung W-m, Faria DB, Endo T, Petranto and Ribeiro LGT: Do
interventions that reduce infarct size alter mortality rate? Clin Res 29.221 A, 1981.
49. Ribeiro LGT, Faria DB, Cheng W-m and Maroko PR: How accurate is the
measurement of experimental infarct size when only selected left ventricular slices are used? Clin Res 29.235A, 1981.
50. Iwasaki T, Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR. The
importance of the source of hyaluronidase in determining its effectiveness in reducing infarct size. Clin Res 29. 210A, 1981.
51. Carvolho MA, Aloan L, Mello MG Jr, Carneiro RD and Ribeiro LGT: Beneficial
effects of verapamil on myocardial ischemic injury Evaluation by precordial ST segment mapping. Clin Res 29:180A, 1981.
52. Faria DB, Iwasaki T, Endo T, Cheung W-m, Ribeiro LGT and Maroko PR.
Calcium Antagonists: Their effectiveness in decreasing the occur ance of ventricular fibrillation and reducing infarct size after a coronary artery occlusion. Am J Cardiol 47.443, 1981.
53. DeBauche TL, Brandon TA, Ribeiro LGT, Holyfield K and Muller RR. Effect of
Prostacyclin on ventricular arrhythmias and intracardiac conduction in myocardial ischemia. Am J Cardiol 47:437, 1981.
15
54. Carvalho MA, Ribeiro LGT, Aloan L, Mello MG, Carneiro RD and Maroko PR: Efeitos beneficos de verapamil sobre o miocardo isquemico -- avaliacao pelo mapeamento precordial do segmento ST (in Portuguese). Arq Bras Cardiol 36(Suppl I):135, 1980.
55. Faria DB, Cheung W-m, Hastie R, Petranto Maroko PR and Ribeiro LGT.
Effect of prostacyclin on infarct size -- analysis of discrepancies. Circulation 64 (Suppl 1 IV):IV-280, 1981.
56. Endo T, Ribeiro LGT, Cheung W-m and Maroko PR: Reduction in hemorrhage
and the extent of necrosis y methoxy-verapamil in dogs with coronary artery reperfusion. Clrculation 64:(Suppl IV):IV-98, 1981.
57. Cheung W-m, Kjekshus H, Ribeiro LGT and Maroko PR: Quantification of
"no-reflow phenomenon" by dual autoradiography after different times of occlusion and its relationship to necrosis. Am Coll Cardiol 49.1047, 1982.
58. Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR: Three-dimensional
analysis of infarct size reduction. Clin Res 30:184A, 1982. 59. Iwasaki T, Lumia FJ, Germon PA, Maranhao V. Biggs R and Ribeiro LGT.
Exercise radionuclide ventriculography--correlation with clinical parameters and the severity of coronary artery disease. Clin Res 30:195A, 1982.
60. Horak JK, Ribeiro LGT, Brandon TA, Ware JA, Solis T and Miller RR. Etanol
and platelet function--demonstration of disparate effects of high and low doses on platelet aggregation. Clin Res 30:194A, 1982.
61. Zalewski A, Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR.
Comparison of the effectiveness of various calcium antagonists in protecting acutely ischemic myocardium Clin Res 30.232A. 1982.
62. Ribeiro LGT, Bowker BL and Maroko PR: BeneficIal effects of berberiane
on early mortality after experimental coronary artery occlusion in rats. Circulation 66(II) II-56, 1982.
63. Vik-Mo H, Maroko PR and Ribeiro LGT: Comparative effects of propanolol,
timolol and metoprotol after coronary occlusion Circulation 66 (II):85, 1982.
64. Zalewski A, Faria DB, Cheung W-m, Ribeiro LGT and Maroko PR. Comparative
effects of five caIcium antagonists on infarct size and mortality after coronary artery occlusion. Circulation 66(II):II-66, 1982.
16
65. Zalewski A, Faria DB, Krol R, Ribeiro LGT and Maroko PR: Striking infarct size reduction y various interventions when the zone at risk is smal. Circulation I (2):660, 1983.
66. Krol R, Maranhao V, Ribeiro LGT and Maroko PR: Usefulness of selective
coronary dye-dilution curves in detecting collateral circulation and evaluating the effects of rugs. Circulation 1(2):702, 1983.
67. Ribeiro LGT, Reitz PM and Sweet CS. Experimental myocardial infartion--
effects of timolol in ischemic injury and myocardial blood flow. Proceedings of the II World Conference on Clinical Pharmacology and Therapeutics. 134, 1983.
68. Vlasses PH, Ribeiro LGT, Rotmensch HH, Bondi J, Hichens M, Loper AG,
Clementi RA, Abrams WB, Ferguson RK. Initial evaluation of transdermal timoiol. Serum concentrations and beta-blockade. Clin Pharmacol and Therapeutics: 35(2) 279, 1984.
69. Ribeiro LGT, Vlasses PH, Bond J, Loper AE, Dunlay MC. Rotmensch HH
Ferguson RK and Abrams WB: Timolol transdermal administration skin flux, pharmacolodynamic effects and skin irritation evaluation. Clin Res 32:246A, 1984.
70. Sweet CS and Ribeiro LGT: Improvement in left ventricular failure by
MK-422 (A new intravenous angiotensin converting enzyme Inhibitor. Clinical Research 32;21AO, 1984.
71. Ribeiro LGT, Gaul SL and Sweet CS: Transmural variation in myocardial
perfusion between the apex and the base of the heart. Clin Res 32 200A, 1984.
72. Vik-Mo H, Ribeiro LGT and Maroko PR. Infarct size reduction by decrease in
free fatty acid metabolish -- additive effects of oxfenicine ana nicotinic acid. Eur Heart J 5:91, 1984.
73. Ribeiro LGT, Fisher MB, Mallis G. Morganroth J, Kostis JB and Irvin JD. Beneficial effects of timolol on ventricular response rate in
patients with chronic atrial fibrillation. Clin Res 32(3).680A, 1984. 74. Ribeiro LGT, Price BA, Marlon A, Pool PE, Salel AE, Whalen JJ and Irvin JD:
Efficacy of timolol in the treatment of malignant ventricular arrhythmias. Clin Res 32(3):681A, 1984.
75. Sweet CS, Ribeiro LGT, Ludden CT and Blaine EH: Hemodynamics and renal
electrolyte atrial natriuretic factor in dogs with acute left ventricular failure. Clin Res 32(3):683A, 1984.
17
76. Sweet CS, Nugent LW, Mulcahy W and Ribeiro LGT. A new experimental heart failure model-beneficial effects of felodipine a potent calcium antagonist. Arq Bras Cardiol 43(1): 55, 1984.
77. Ribeiro LGT, Walker JF, Whalen JJ, Davies RO and Smith, WM: Benefícial
effects of enalapril, a new angiotensin converting enzyme inhibitor, in the treatment of hypertenison and cogestive heart failure. Arq Bras Cardiol 43(1): 109, 1984.
78. Hock CE, Ribeiro LGT and Lefer AM. Effects of enalaprilic acid (MK-422)
in myocardial infarction. Federation Proceedings 43.355, 1984. 79. Sweet CS, Ribeiro LGT, Lunden CT, Blaine EH, Slater EE, Nussberger J and
Nutt RF: Hemodynamic and renal electrolyte effects of synthetic atrial natriuretic factor in dogs with acute left ventricular failure.
Circulation 70(4):II-333, 1984. 80. Vik-Mo H, Mjos OD, Maroko PR, Ribeiro LGT and Neely JR. Effects of nico
tinic acid, oxfenicine and timolol on fatty acid metabolism in normal and ischemic myocardium in dogs. J Molec Cell Cardiol 16(2):48, 1984
81. Saris SD, Lowenthal DT, Porter RS, Bondi J, Loper AE, Dunlay MC, Goodwin
MJ and Ribeiro LGT: Seven-day transdermal administration of timolol. Clin Pharm and Thera 37(2):226, 1985.
82. Brum JM, Dotson BS, Ribeiro LGT, Bove AA, Ghat G. Neuropeptide y coronary
vasoconstriction is independent on adrenergic and muscarinic receptors. J Am Coli Cardiol 7(2).251A. 1986.
83. Smith III EF, Egan JW, Goodman FR, Zimmerman MB and Ribeiro LGT.
Cardioprotective effect of the angiotensin converting enzyme Inhibitor CGS 14831 in rats FedProc 45.689, 1986.
84. Vik-Mo H, Ribeiro LGT, Maroko PR. A model of acute left ventricular
failure in dogs--hemodynamic and metabolic evaluation Proc of x Worl Cong Card 105, 1986.
85. Vik-Mo H, Ribeiro LGT, Maroko PR: Myocardial oxygen consumption after
corwin and dobutamine in the normal and failing left ventricle. Proc of X World Cong Card 518, 1986.
87. Watters JT, Benz JR, Maher TF, Ivankoe LD, Hurley ME and Ribeiro LGT: CGS
14824A, a new non-sulfhydryl angiotensin converting enzyme inhibitor (ACEI) -- efficacy in patients with mild to moderate hypertension. J Clin Pharm 27(9). 718, 1987.
18
87. deSilva JK, Hurley ME, WecIaw-Hakim C and Ribeiro LGT. Efficacy and safety of CGS 16617 a new non-thiol angiotensin converting enzyme inhibitor, in patients with mild to moderate hypertension. J Clin Pharm 27(9).717, 1987.
88. Ribeiro LGT, Brandon TA, Miller RR. Beneficial effects of methozy-verapamil on early mortality in experimental coronary artery occlusion. Clinical Research 32, 198A, 1980.
89. Ribeiro LGT, Reduto LA, Brandon TA, Taylor AA, Hopkin DG and Miller RR. Effects of Prostacyclin on hemodynamics, regional blood flow, infarct size and mortality in experimental myocardial infarction. AFCR Cardiovascular, 81, 194A, 1980.
CONGRESSOS MÉDICOS ONDE O DR. LAIR RIBEIRO FOI COMO PARTICIPANTE OU CONFERENCISTA
1. January 23-25, 1996. The seven habits of highly effective people. COVEY LEADERSHIP CENTER, INC. 2. May, 1st 2001. Has effectively contributed with the purposes of the 30th IFTDO World Conference of Training and Development, accomplished at PUCRS’ Event Center, in Porto Alegre City Rio Grande do Sul State, Brazil, Thus grants that International Speaker Certificate. ABTD AND DEVELOPMENT BRAZILIAN SOCIETY. 3. 08 de Dezembro de 2001. Participou do Curso de Medicina Quântica Integral de acordo com seus Estatutos, com a Carga Horária de 100 Horas. INSTITUTO BRASILEIRO DE METODOLOGIA QUÂNTICA (IBMQ-lab). 4. 31 de Maio de 2006. Confere o Mérito por relevantes serviços prestados á cidade e á coletividade de Juiz de Fora. Mérito Comendador Henrique Guilherme Fernando Halfeld. 5. 29 e 31 de Março de 2007, Realizou abertura do IV Congresso Mundial Medicina Estética da IAAM/ASIME, com o tema “ Marketing na Área da Estética: A combinação da prosperidade com a Ética”. ASSOCIAÇÃO INTERNACIONAL DE MEDICINA ESTÉTICA (A.S.I.M.E) . 6. 12,13 e 14 de Setembro de 2007. Participou na qualidade de Palestrante, proferindo a palestra: Envelhecer sem Ficar Velho e Doente. XI Congresso Brasileiro de Nutrologia, XII Conferência sobre Obesidade, IV Conferência de Direito Humano à Alimentação Adequada, V Annual Meeting International Colleges for Advancements of Nutrition. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA ( ABRAN). 7. 12,13 e 14 de Setembro de 2007. Participou na qualidade de Palestrante, proferindo a palestra: Marketing com Ética na Área da Saúde.
19
XI Congresso Brasileiro de Nutrologia, XII Conferência sobre Obesidade, IV Conferência de Direito Humano à Alimentação Adequada, V Annual Meeting International Colleges for Advancements of Nutrition. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 8. 12,13 e 14 de Setembro de 2007. Por sua participação no XI Congresso Brasileiro de Nutrologia, XII Conferência sobre Obesidade, IV Conferência de Direito Humano á Alimentação Adequada, V Annual Meeting International Colleges for Advancements of Nutrition como Participante. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA ( ABRAN). 9. 14 e 15 de Março de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo I). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 10. 18 e 19 de Abril de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo II). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 11. 16 e 17 de Maio de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo III). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 12. 05 de Junho de 2008. Participou do Curso pré-congresso sobre “ Avanços no Diagnóstico Laboratorial em Alergias”. INSTITUTO DE MICROECOLOGIA. 13. 06,07 e 08 de Junho de 2008. Na qualidade de palestrante com o tema: Paradigma do Lipograma. XXI CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS LIVRES. A.M.B.O. 14. 06,07 e 08 de Junho de 2008. Na qualidade de Congressista. XXI CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS LIVRES. A.M.B.O. 15. 10 a 13 de Junho de 2008. Conferido como Ministrador do Curso “ Como Envelhecer sem Ficar Velho”. Durante o 4º Congresso Internacional de Odontologia ABO São Paulo. CIODONTO.
20
16. 13 e 14 de Junho de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo IV). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 17. 11 e 12 de Julho de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo V). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 18. 13 de Julho de 2008. Participou do II Curso de Capacitação em Diabetes. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 19. 15 e 16 de Agosto de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo VI). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 20. 30 de Agosto a 02 de Setembro de 2008. Ministrou o 3º Congresso Científico Latino- Americano de Estética. BEATY FAIR ESTÉTICA. 21. 03,04 e 05 de Setembro de 2008. Por sua participação no XII Congresso Brasileiro de Nutrologia, XIII Conferência sobre Obesidade, V Conferência de Direito Humano à Alimentação Adequada, VI Annual Meeting International Colleges for Advancements of Nutrition como Participante. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 22. 03,04 e 05 de Setembro de 2008. Por sua participação no XII Congresso Brasileiro de Nutrologia, XIII Conferência sobre Obesidade, V Conferência de Direito Humano á Alimentação Adequada, VI Annual Meeting International Colleges for Advancements of Nutrition como Palestrante, proferindo a palestra Gorduras Boas e Ruins. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 23. 17 e 18 de Outubro de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo VII). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 24. 14 e 15 de Novembro de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual (HSPE), São Paulo/ SP (Módulo VIII). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN).
21
25. 12 e 13 de Dezembro de 2008. Participou do VI Curso Nacional de Formação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual ( HSPE), São Paulo/ SP (Módulo IX). ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 26. Dezembro de 2008. Concluiu o VI Curso Nacional de Fomação e Atualização em Nutrologia realizado no Centro de Estudos em Educação Médica Continuada do Hospital do Servidor Público Estadual (HSPE), São Paulo/ SP. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA (ABRAN). 27. 19 a 21 de Março de 2009. Participou do VI Congresso Mundial de Medicina Estética da IAAM/ASIME, VIII Simpósio Internacional de Medicina Antienvelhecimento e X Jornada Brasileira de Dermatologia Estética, entre outros. 28. 19 a 21 de Março de 2009. Participou na qualidade de Palestrante do (a) Conferência, Modulação Hormonal Bioidêntica: um dos pilares da Estética e do Antienvelhecimento do VI Congresso Mundial de Medicina Estética da IAAM/ASIME, VIII Simpósio Internacional de Medicina Antienvelhecimento e X Jornada Brasileira de Dermatologia Estética, entre outros. 29. 19 a 21 de Março de 2009. Participou na qualidade de Palestrante do (a) Painel, Envelhecimento, Subtema: Oxigem Multistep Therapy- A Medicina de Von Ardenne aplicada ao Antienvelhecimento do VI Congresso Mundial de Medicina Estética da IAAM/ASIME, VIII Simpósio Internacional de Medicina Antienvelhecimento e X Jornada Brasileira de Dermatologia Estética, entre outros. 30. 19 a 21 de Março de 2009. Participou na qualidade de Palestrante do (a) Painel, Atualidades, Subtema: O Valor da Hidro-Ozonioterapia na Saúde e na Estética do VI Congresso Mundial de Medicina Estética da IAAM/ASIME, VIII Simpósio Internacional de Medicina Antienvelhecimento e X Jornada Brasileira de Dermatologia Estética, entre outros.
31. 14 de Maio de 2009. Participou da Reunião Científica de Nutrologia, que abordou os temas: “ Abordagem Nutrológica do Paciente Oncológico” e “ Nutrição em Cuidados Paliativos”, promovida pelo Departamento de Nutrologia da Associação Paulista de Medicina. ASSOCIAÇÃO BRASILEIRA DE NUTROLOGIA ( ABRAN). 32. 29,30 e 31 de Maio de 2009. Na qualidade de palestrante com o tema: Helioterapia, Exposição Inteligente a Luz Solar. Eficaz e Erroneamente Abandonada. XXII CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS LIVRES . A.M.B.O. 33. 29,30 e 31 de Maio de 2009. Na qualidade de palestrante com o tema: O Valor da Hidro- Ozonioterapia na Estética e na Saúde. XXII CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS
22
LIVRES. A.M.B.O. 34. 29,30 e 31 de Maio de 2009. Na qualidade de palestrante com o tema, TRH e Longevidade. XXII CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS LIVRES A.M.B.O. 35. 29,30 e 31 de Maio de 2009. Na qualidade de congressista. XXII CONGRESSO INTERNACIONAL DE PRÁTICA ORTOMOLECULAR E RADICAIS LIVRES. A.M.B.O. 36. 02-17-2009. Is an Active Member of A4M, a Society of Physicians and Scientists dedicated to enhancing the quality and extending the length of the human lifespan. AMERICA ACADEMY OF ANTI-AGING MEDICINE. 37. 15,16 e 17 de Setembro de 2011. Participou como Coordenador do Módulo “ Fadiga Adrenal- uma enfermidade da civilização moderna”, ministrado pelo Prof. Dr. James L. Wilson. II Fórum Internacional de Nutrição Funcional, Prevenção de Doenças Degenerativas e Envelhecimento com Qualidade de Vida, CHRONOS 2011. 38. 28 de Outubro de 2011. Participou como Ministrante da Palestra “O Futuro do mercado Farmacêutica- mudar para permanecer”, no Seminário Internacional “ A Arte de ser Farmacêutico.” CRF- SP.
39. December 11, 2011. Participated in the educational activity titled, Restoring Gastrointestinal Equilibrium: Practical Applications for Understanding , Assessingg, and Treating Gut Dysfunction. The Institute for Functional Medicine is accredited by the Accreditation Council for Continuing Medical Education ( ACCME) to provide continuing medical education for physicians.
40. 15,16 e 17 de Março de 2012. Participou do IX Congresso Mundial de Medicina
23
Estética, II Simpósio Internacional de Antienvelhecimento, XIII Jornada Brasileira de Dermatologia, I Simpósio Internacional de Laser e Fotomedicina, entre outros. ASIME.
41. 15,16 e 17 de Março de 2012. Participou na qualidade de Palestrante com o tema: Como eu Prescrevo Modulação Hormonal Bioidêntica. IX Congresso Mundial de Medicina Estética, II Simpósio Internacional de Antienvelhecimento, XIII Jornada Brasileira de Dermatologia, I Simpósio Internacional de Laser e Fotomedicina, entre outros. ASIME.
42. 15,16 e 17 de Março de 2012. Participou na qualidade de Presidente de Mesa do (a) II Simpósio Internacional de Antienvelhecimento. IX Congresso Mundial de Medicina Estética, II Simpósio Internacional de Antienvelhecimento, XIII Jornada Brasileira de Dermatologia, I Simpósio Internacional de Laser e Fotomedicina, entre outros. ASIME.
43. 15,16 e 17 de março de 2012. Participou na qualidade de palestrante do (a) Mini- Conferência: Evolução da Hidro Ozônioterapia na Estética e no Antienvelhecimento. IX Congresso Mundial de Medicina Estética, II Simpósio Internacional de Antienvelhecimento, XIII Jornada Brasileira de Dermatologia, I Simpósio Internacional de Laser e Fotomedicina, entre outros. ASIME.
44. 15,16 e 17 de Março de 2012. Participou na qualidade de Palestrante, Palestra: Otimização do desempenho cerebral uso inteligente de suplementos que melhoram a cognição. IX Congresso Mundial de Medicina Estética, II Simpósio Internacional de Antienvelhecimento, XIII Jornada Brasileira de Dermatologia, I Simpósio Internacional de Laser e Fotomedicina, entre outros. ASIME.
45. 23,24 e 25 de Agosto de 2012. Participou como Apresentador da Conferência “ O Sucesso não ocorre por acaso. É simples, mas não é fácil!” IV Brazil International Meeting . BIOMET. 3i BRASIL.
46. 21 de Outubro de 2012. Participou do Curso The Life PLan com Dr. Jeffry Life. 4º Meeting International IUCAP (Instituto Universitário Camargo pedrosa).
24
47. 07,08 e 09 de Março de 2013. Participou na qualidade de Palestrante, Palestra: Baixas Doses de Naltrexona (LDN) no Tratamento de HIV/AIDS, Câncer, Doenças Autoimunes & Neurodegenerativas. X Congresso Mundial de Medicina Estética, I Congresso Nacional de Dermatologia do CBD, III Simpósio em Prevenção e Tratamento de Doenças Relacionadas à Idade, entre outros. ABME/ASIME.
48. 07,08 e 09 de Março de 2013. Participou na qualidade de Presidente de Mesa do (a) Palestra A Abordagem Termográfica na Prevenção, Detecção e Follow– Up de Incompatibilidade Alimentar e Câncer. X Congresso Mundial de Medicina Estética, I Congresso Nacional de Dermatologia do CBD, III Simpósio em Prevenção e Tratamento de Doenças Relacionadas à Idade, entre outros. ABME/ASIME.
49. 26,27 e 28 de Abril de 2013. Participou do III Simpósio Medico Brasileiro do Bi- Digital O- Ring Test.
50. 21 de Outubro de 2013. Por sua participação no 1º Congresso Gaúcho de Arquitetura Facial e Coerporal como Palestrante.
51. 01 de Maio de 2014. Realizou o 1º Pré-Congresso Tratamento Bioregulatório da Inflamação. FAPES- Fundação de Apoio à Pesquisa e Estudo na Área da Saúde.
52. October 27, 2014. Attended a one day Seminar on Cell Therapy " Revitalization and Activation of the Immune System".
Conducted by Dr. Kurt Pfützner. He also acquired a profound Knowledge in the field of Cell Therapy.
Seminar was organized by German-French Soiety for Thymus Therapy.
53. October 27, 2014. Attended a one day Seminar on Cell Therapy “Fundamental Therapeutic Options of Xenogene Peptides in the Natural Medicine” conducted by Dr. Med. Michael Männel. He also acquired a profound Knowledge in the field of Cell Therapy.
Seminar was organized by German-French Soiety for Thymus Therapy.
25
54. Octorber 28th to November 3rd, 2014. Participated in a week of continuing education sessions in Germany involving training courses on Biological Medicine, Lectures by renowned German physicians and researchers, as sponsored by Occidental Institute Research Foundation.
55. 26,27 e 28 de Março de 2015. Participou na qualidade de Presidente de Mesa do (a) Palestra, Enxaqueca Só Tem Quem Quer- Abordagem Integrativa no Tratamento de Enxaquecas Crônicas e Resistentes ao Tratamento. XII Congresso Mundial de Medicina Estética, III Congresso Nacional de Dermatologia CBD, V Simpósio em Prevenção & Tratamento de Doenças Relacionadas à Idade. (ABME/ISBRAE).
56. 26,27 e 28 de Março de 2015. Participou na qualidade de Palestrante do (a) Palestra, Vitamina D3- O Hormônio Esteroidal mais Potente do Corpo- Potencial Terapêutico do Uso da Vit 3 como Nutracêutico. XII Congresso Mundial de Medicina Estética, III Congresso Nacional de Dermatologia CBD, V Simpósio em Prevenção & Tratamento de Doenças Relacionadas à Idade. (ABME/ISBRAE).
57. 26,27 e 28 de Março de 2015. Participou na qualidade de Presidente de Mesa do (a) Palestra, Biofísica Integrativa- Utilização de Ferramentas Simples e eficazes no Diagnóstico e Otimização Terapêutica de Patologias Metabólicas & Degenerativas. XII Congresso Mundial de Medicina Estética, III Congresso Nacional de Dermatologia CBD, V Simpósio em Prevenção & Tratamento de Doenças Relacionadas à Idade. (ABME/ISBRAE).
58. 26,27 e 28 de Março de 2015. Participou na qualidade de Presidente de Mesa do(a) Palestra, Inflamação Crônica como Parte da Fisiopatologia de Todas as Doenças Degenerativas- Diagnóstico & Conduta Terapêutica. XII Congresso Mundial de Medicina Estética, III Congresso Nacional de Dermatologia CBD, V Simpósio em Prevenção & Tratamento de Doenças Relacionadas à Idade . (ABME/ISBRAE).
59. May 2015. successfully completed the intensive course ONDAMED aprensentado by Binder Institute for Personalized Medicine. THE BINDER INSTITUTE.
26
60. Oct. 30, 2015. Attended an Ozone Workshop on the Use of Ozone in Medicine. Medical Association for the Use of Ozone in Prevention and Therapy. 61. October 27th to November 2nd, 2015. Participated in a week of continuing education sessions in germany, involving training courses on Biological Medicine. Lectures by renowned German physicians and researchers, as sponsored by Occidental Institute Research Foundation.
62. 28.11./ 29.11.2015. 3 rd International Congress on Integrative Medicine Hallmarks in Cancer Treatments: Immunotherapy, Stem Cell & Nutrition.
